Semanteon Capital Management LP Acquires New Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Semanteon Capital Management LP acquired a new stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 32,864 shares of the medical technology company's stock, valued at approximately $302,000.

Other institutional investors have also bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Alphatec during the 4th quarter worth about $29,000. Nisa Investment Advisors LLC increased its stake in shares of Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock valued at $43,000 after acquiring an additional 4,234 shares during the period. Newton One Investments LLC bought a new stake in Alphatec during the fourth quarter worth approximately $50,000. XTX Topco Ltd acquired a new stake in Alphatec in the third quarter worth approximately $69,000. Finally, AlphaQuest LLC bought a new position in Alphatec during the 4th quarter valued at $80,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ATEC shares. Piper Sandler boosted their price objective on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Barclays raised their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Tuesday, January 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $16.00 target price on shares of Alphatec in a research note on Thursday, February 27th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Alphatec presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.67.

Remove Ads

Insider Activity at Alphatec

In other Alphatec news, COO Scott Lish sold 27,453 shares of the stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $11.49, for a total value of $315,434.97. Following the completion of the sale, the chief operating officer now owns 867,677 shares in the company, valued at $9,969,608.73. This represents a 3.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Patrick Miles sold 12,691 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $10.64, for a total transaction of $135,032.24. Following the transaction, the chief executive officer now owns 5,857,603 shares in the company, valued at approximately $62,324,895.92. This represents a 0.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 337,321 shares of company stock valued at $3,828,060. Company insiders own 22.80% of the company's stock.

Alphatec Trading Down 0.7 %

Shares of Alphatec stock traded down $0.07 during trading on Wednesday, hitting $10.25. The stock had a trading volume of 1,040,861 shares, compared to its average volume of 1,968,299. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $14.54. The stock has a 50 day simple moving average of $10.94 and a 200 day simple moving average of $8.92. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The company has a market capitalization of $1.48 billion, a PE ratio of -8.01 and a beta of 1.39.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The firm had revenue of $176.79 million for the quarter, compared to analysts' expectations of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. On average, research analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.